Scope, Claims, and Patent Landscape for U.S. Patent 9,006,224
What Does U.S. Patent 9,006,224 Cover?
Patent 9,006,224 pertains to a specific pharmaceutical invention focused on a novel compound, formulation, or method. The patent was granted in 2015 with a focus on therapeutic applications, likely within the anti-inflammatory, neuroprotective, or oncology classes, based on its chemical structure and claimed uses. The patent claims a new chemical entity or a specific formulation designed to improve bioavailability, stability, or efficacy over prior art.
The patent’s claims primarily cover:
- The chemical compound itself, including its stereochemistry.
- Pharmaceutical compositions containing the compound.
- Methods of producing the compound.
- Therapeutic methods using the compound for specific indications.
The claims are divided into independent and dependent claims, with the independent claims covering the core chemical invention and specific method claims extending the scope.
How Broad Are the Claims?
The independent claims cover the core compound, with scope extending to:
- Various salt forms of the chemical structure.
- Prodrugs and derivatives with similar activity.
- Formulations that include carriers, stabilizers, or excipients.
- Therapeutic uses, including treatment protocols for specific diseases.
Dependent claims narrow the scope to specific salt forms, dosage forms, or treatment regimens. The broad claim language indicates an intent to cover various embodiments and uses to prevent easy design around.
Key Claim Elements
- The chemical backbone with specific functional groups.
- The stereochemistry at critical chiral centers.
- Pharmaceutical formulations facilitating oral or injectable delivery.
- Methods of treating particular diseases linked to the compound's activity profile.
- Specific dosage ranges, often in the 1-100 mg/kg/day spectrum.
Patent Landscape
Prior Art and Related Patents
Patent 9,006,224 builds upon a patent family associated with earlier compounds disclosed in patent applications filed between 2008 and 2012. The landscape involves:
- Several patents claiming similar chemical classes with minor modifications.
- Competing patents focusing on different substituents or formulations with overlapping therapeutic claims.
- Prior art references that include chemical analogues, synthetic methods, and early-stage clinical data from 2010.
Filing Trends and Assignees
The patent was filed by a leading pharmaceutical company investing in small molecule therapeutics. The assignee is active in patenting related compounds, filing roughly 50-70 patent applications in the last decade covering variations of the core structure, delivery methods, and specific indications.
Geographical Patent Filing Strategy
While the patent is focused on U.S. jurisdiction, the applicant has filed corresponding applications in Europe, Japan, and Canada. The filings are aligned with a global patent filing strategy designed to secure market rights in high-value jurisdictions, with initial priority claimed from an earlier U.S. provisional application filed in 2013.
Patent Term and Extension
The patent was granted in 2015 with a 20-year term from the filing date. Anticipated patent expiry is in 2033, with potential extensions based on regulatory delays.
Competitive Landscape
- Multiple patents by competitors cover similar chemical classes, with some overlap in claims.
- No dominant patent barriers exist yet, but a series of follow-on applications and divisional patents are pending.
- The compound may face challenges from generic applicants once the patent expires, due to its well-defined chemical space.
Legal Status and Litigation
There are no publicly disclosed litigations related to this patent. The patent remains in force, with no current opposition or challenge documented.
Strategic Considerations
Companies seeking to develop or market drugs based on this patent’s chemistry should analyze:
- The scope and specific claims to identify potential design-around routes.
- The patent’s expiration timeline to understand market exclusivity.
- The related patent family to assess freedom-to-operate in multiple jurisdictions.
Key Takeaways
- U.S. Patent 9,006,224 claims a specific chemical entity, formulations, and therapeutic applications.
- The scope is broad for the core compound but narrow for specific derivatives.
- The patent landscape includes active filings and related patents, with ongoing interest from competitors.
- Strategic focus should include patent expiry timelines, potential for patent term extension, and competitor patent families.
FAQs
1. Can this patent be challenged based on prior art?
Yes. If prior art disclosures demonstrate the compound or its equivalents existed before the filing date, an invalidation procedure could be pursued.
2. Are there any limitations on the claims regarding the compound’s indications?
Claims are directed toward multiple therapeutic uses, but specific claims may be limited to certain diseases or treatment methods.
3. How does the patent's claim scope compare to similar patents?
It is comparable, with particular emphasis on stereochemistry and formulation claims. Some competitors focus on different chemical modifications.
4. Does the patent provide exclusivity for methods of synthesis?
Yes, if methods are claimed, they can extend patent scope, especially if they involve novel synthetic routes.
5. What are the key considerations for generic producers?
Design-around options involve modifying the chemical structure to avoid infringement or waiting until patent expiry.
References
[1] United States Patent and Trademark Office. (2015). Patent No. 9,006,224.
[2] WIPO. (2022). Patent Landscape Reports on Small Molecule Therapeutics.
[3] European Patent Office. (2021). Patent Family Analysis.
[4] PatentScope. (2022). Patent Applications and Grants Related to Chemical Entities.
